MYC and plasma cell myeloma: Furthermore, the BM microenvironment can protect myeloma cells from drug therapies by inducing quiescence, and a subpopulation of myeloma cancer stem cells that post-transcriptionally lose CD138 expression are an extramedullary pool of c-Myc dependent drug-resistant cells (4).